Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated:  4/5/2013
Ruikang Hospital
mi
from
Nanning,
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Status: Enrolling
Updated: 4/5/2013
Ruikang Hospital
mi
from
Nanning,
Click here to add this to my saved trials
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  4/8/2013
Massachusetts General Hospital
mi
from
Boston, MA
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 4/8/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  4/8/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 4/8/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  4/8/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 4/8/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
Status: Enrolling
Updated:  4/8/2013
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
Status: Enrolling
Updated: 4/8/2013
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Communicating Smoking Risks Through Graphic Warning Labels
Communicating Smoking Risks Through Graphic Warning Labels
Status: Enrolling
Updated:  4/8/2013
Annenberg Public Policy Center
mi
from
Philadelphia, PA
Communicating Smoking Risks Through Graphic Warning Labels
Communicating Smoking Risks Through Graphic Warning Labels
Status: Enrolling
Updated: 4/8/2013
Annenberg Public Policy Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Communicating Smoking Risks Through Graphic Warning Labels
Communicating Smoking Risks Through Graphic Warning Labels
Status: Enrolling
Updated:  4/8/2013
Lazenby Hall, Ohio State University
mi
from
Columbus, OH
Communicating Smoking Risks Through Graphic Warning Labels
Communicating Smoking Risks Through Graphic Warning Labels
Status: Enrolling
Updated: 4/8/2013
Lazenby Hall, Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Status: Enrolling
Updated:  4/9/2013
Memorial Hospital
mi
from
Pawtucket, RI
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Status: Enrolling
Updated: 4/9/2013
Memorial Hospital
mi
from
Pawtucket, RI
Click here to add this to my saved trials
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Status: Enrolling
Updated:  4/9/2013
Rhode Island Hospital
mi
from
Providence, RI
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Status: Enrolling
Updated: 4/9/2013
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Status: Enrolling
Updated:  4/9/2013
Miriam Hospital
mi
from
Providence, RI
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Status: Enrolling
Updated: 4/9/2013
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Status: Enrolling
Updated:  4/9/2013
Roger Williams Medical Center
mi
from
Providence, RI
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Status: Enrolling
Updated: 4/9/2013
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Pilot Trial to Determine Organ Motion Using Active Breathing Control (ABC) in Patients With Pancreatic Cancer
A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control (ABC) in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  4/10/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Pilot Trial to Determine Organ Motion Using Active Breathing Control (ABC) in Patients With Pancreatic Cancer
A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control (ABC) in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 4/10/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function
A Phase I, Open-label, Multi-center Study to Evaluate the Pharmacokinetics and Safety of Oral Panobinostat in Patients With Advanced Solid Tumors and Varying Degrees of Renal Function
Status: Enrolling
Updated:  4/15/2013
University of Utah / Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function
A Phase I, Open-label, Multi-center Study to Evaluate the Pharmacokinetics and Safety of Oral Panobinostat in Patients With Advanced Solid Tumors and Varying Degrees of Renal Function
Status: Enrolling
Updated: 4/15/2013
University of Utah / Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Clearview Cancer Center
mi
from
Huntsville, AL
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Clearview Cancer Center
mi
from
Huntsville, AL
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Radiology Associates of Sacramento/Sutter Cancer Center
mi
from
Sacramento, CA
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Radiology Associates of Sacramento/Sutter Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Emory University
mi
from
Atlanta, GA
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Northside Hospital/GA Cancer Specialists
mi
from
Atlanta, GA
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Northside Hospital/GA Cancer Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
University of Louisville
mi
from
Louisville, KY
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Hematology and Oncology Assoc. at Bridgeport
mi
from
Tupelo, MS
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Hematology and Oncology Assoc. at Bridgeport
mi
from
Tupelo, MS
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Washington University/Alvin J. Siteman Cancer Center
mi
from
St. Louis, MO
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Washington University/Alvin J. Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Providence Portland Medical Center/Providence Cancer Center
mi
from
Portland, OR
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Providence Portland Medical Center/Providence Cancer Center
mi
from
Portland, OR
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Hospital Italiano de Buenos Aires
mi
from
Buenos Aires,
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Hospital Italiano de Buenos Aires
mi
from
Buenos Aires,
Click here to add this to my saved trials
Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)
Using Technology to Promote Activity in Women at Elevated Breast Cancer Risk
Status: Enrolling
Updated:  4/17/2013
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)
Using Technology to Promote Activity in Women at Elevated Breast Cancer Risk
Status: Enrolling
Updated: 4/17/2013
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
chemQbiosciences:Manual Liquid Based Cytology
chemQbiosciences:Manual Liquid Based Cytology
Status: Enrolling
Updated:  4/17/2013
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
chemQbiosciences:Manual Liquid Based Cytology
chemQbiosciences:Manual Liquid Based Cytology
Status: Enrolling
Updated: 4/17/2013
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Exercise in Breast Cancer Survivors
Exercise in Breast Cancer Survivors: Analysis of Angiogenic Profile
Status: Enrolling
Updated:  4/22/2013
University of Mississippi Health Care
mi
from
Jackson, MS
Exercise in Breast Cancer Survivors
Exercise in Breast Cancer Survivors: Analysis of Angiogenic Profile
Status: Enrolling
Updated: 4/22/2013
University of Mississippi Health Care
mi
from
Jackson, MS
Click here to add this to my saved trials
A Safety Study of Oral ZSTK474 in Patients With Cancer
A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated:  4/23/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Safety Study of Oral ZSTK474 in Patients With Cancer
A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated: 4/23/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of Oral ZSTK474 in Patients With Cancer
A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated:  4/23/2013
Washington University
mi
from
St. Louis, MO
A Safety Study of Oral ZSTK474 in Patients With Cancer
A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated: 4/23/2013
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Safety Study of Oral ZSTK474 in Patients With Cancer
A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated:  4/23/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
A Safety Study of Oral ZSTK474 in Patients With Cancer
A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated: 4/23/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated:  4/24/2013
Karmanos Cancer Center
mi
from
Detroit, MI
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated: 4/24/2013
Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated:  4/24/2013
The University of Oklahoma Health Science Center
mi
from
Oklahoma City, OK
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated: 4/24/2013
The University of Oklahoma Health Science Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated:  4/24/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated: 4/24/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated:  4/24/2013
Sarah Cannon Research Institute
mi
from
Nashville, TN
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated: 4/24/2013
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
A Phase 1, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/24/2013
Clinical Research Facility
mi
from
Ann Arbor, MI
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
A Phase 1, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/24/2013
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
A Phase 1, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/24/2013
Clinical Research Facility
mi
from
New York, NY
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
A Phase 1, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/24/2013
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
A Phase 1, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/24/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
A Phase 1, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/24/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated:  4/24/2013
New York Presbyterian-Weill Cornell Medical Center
mi
from
New York, NY
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated: 4/24/2013
New York Presbyterian-Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated:  4/24/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated: 4/24/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated:  4/24/2013
Virginia Mason Medical Center
mi
from
Seattle, WA
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated: 4/24/2013
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated:  4/24/2013
Yale-New Haven Hospital
mi
from
New Haven, CT
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated: 4/24/2013
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients
Assessment of the Prevalence of Sexual Dysfunction, Depression, and Anxiety in Underserved and Minority Patients With Gynecologic Cancers
Status: Enrolling
Updated:  4/26/2013
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients
Assessment of the Prevalence of Sexual Dysfunction, Depression, and Anxiety in Underserved and Minority Patients With Gynecologic Cancers
Status: Enrolling
Updated: 4/26/2013
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients
Assessment of the Prevalence of Sexual Dysfunction, Depression, and Anxiety in Underserved and Minority Patients With Gynecologic Cancers
Status: Enrolling
Updated:  4/26/2013
Lyndon B. Johnson (LBJ) General Hosptial
mi
from
Houston, TX
Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients
Assessment of the Prevalence of Sexual Dysfunction, Depression, and Anxiety in Underserved and Minority Patients With Gynecologic Cancers
Status: Enrolling
Updated: 4/26/2013
Lyndon B. Johnson (LBJ) General Hosptial
mi
from
Houston, TX
Click here to add this to my saved trials
Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA
CCG-LTFI: A Groupwide Protocol for Collecting Follow- up Data
Status: Enrolling
Updated:  4/29/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA
CCG-LTFI: A Groupwide Protocol for Collecting Follow- up Data
Status: Enrolling
Updated: 4/29/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Ixabepilone to Treat Cervical Cancer
A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer
Status: Enrolling
Updated:  5/1/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Ixabepilone to Treat Cervical Cancer
A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer
Status: Enrolling
Updated: 5/1/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Five-Year Quality of Life Study for Cancer Patients
A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLDSM ) Chemotherapy and Nutrition Therapy in the Treatment of Cancer - The IPTLDSM QoL Broad Study
Status: Enrolling
Updated:  5/1/2013
The Kotsanis Institute
mi
from
Grapevine, TX
A Five-Year Quality of Life Study for Cancer Patients
A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLDSM ) Chemotherapy and Nutrition Therapy in the Treatment of Cancer - The IPTLDSM QoL Broad Study
Status: Enrolling
Updated: 5/1/2013
The Kotsanis Institute
mi
from
Grapevine, TX
Click here to add this to my saved trials
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
A Prospective, Double-blind Randomized Phase III Study of 300 mg Versus 150 mg Erlotinib in Current Smokers With Locally Advanced or Metastatic NSCLC in Second-line Setting After Failure on Chemotherapy (CURRENTS)
Status: Enrolling
Updated:  5/7/2013
Clinical Research Facility
mi
from
Omaha, NE
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
A Prospective, Double-blind Randomized Phase III Study of 300 mg Versus 150 mg Erlotinib in Current Smokers With Locally Advanced or Metastatic NSCLC in Second-line Setting After Failure on Chemotherapy (CURRENTS)
Status: Enrolling
Updated: 5/7/2013
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Phase 2 Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer
Status: Enrolling
Updated:  5/8/2013
The Urology Center of Colorado
mi
from
Denver, CO
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Phase 2 Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer
Status: Enrolling
Updated: 5/8/2013
The Urology Center of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Phase 2 Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer
Status: Enrolling
Updated:  5/8/2013
Urology Clinics of North Texas
mi
from
Dallas, TX
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Phase 2 Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer
Status: Enrolling
Updated: 5/8/2013
Urology Clinics of North Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Phase 2 Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer
Status: Enrolling
Updated:  5/8/2013
Urology San Antonio Research
mi
from
San Antonio, TX
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Phase 2 Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer
Status: Enrolling
Updated: 5/8/2013
Urology San Antonio Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
University Of Florida Hepatology
mi
from
Gainesville, FL
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
University Of Florida Hepatology
mi
from
Gainesville, FL
Click here to add this to my saved trials